NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has made significant strides in developing innovative anti-infective products, particularly in the fields of ophthalmology and dermatology. With a focus on its proprietary Avenova® solution, NovaBay offers unique antimicrobial treatments that stand out for their effectiveness and safety profile. The company has established a strong market position, recognised for its commitment to addressing unmet medical needs through advanced science. Over the years, NovaBay has achieved notable milestones, including successful product launches and strategic partnerships, solidifying its reputation as a leader in the development of novel therapies.
DitchCarbon Score
How does NovaBay Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
NovaBay Pharmaceuticals, Inc.'s score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
NovaBay Pharmaceuticals, Inc.'s reported carbon emissions
NovaBay Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the company may be engaged in industry-standard practices aimed at sustainability and reducing environmental impact, which is increasingly important in the pharmaceutical sector. As the industry evolves, it is likely that NovaBay will align with broader climate initiatives and set measurable targets in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
NovaBay Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
